Substituted pyrido-pyridazine derivatives which enhance cognition via the GABA-A receptors
申请人:Merck Sharp & Dohme Ltd.
公开号:US07148222B2
公开(公告)日:2006-12-12
The present invention discloses a compound of formula 1, or a pharmaceutically acceptable salt thereof: wherein X1 represents hydrogen, halogen, C1-6 alkyl, trifluoromethyl or C1-6 alkoxy; X2 represents hydrogen or halogen; Y represents a chemical bond, an oxygen atom, or a —NH— linkage; Z represents an optionally substituted aryl or heteroaryl group; R1 represents hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, —ORa, —SRa, —SORa, —SO2Ra, —SO2NRaRb, NRaRb, —NRaCORb, —NRaCO2Rb, —CORa, —CO2Ra, —CONRaRb or —CRa&═NORb; and Ra and Rb independently represent hydrogen, hydrocarbon or a heterocyclic group; a pharmaceutical composition comprising it; its use in a method of treatment; use of it to manufacture a medicament; and a method of using it to prevent or treat anxiety, convulsions or cognitive disorders.
本发明揭示了化合物1的结构,或其药学上可接受的盐:其中,X1代表氢,卤素,C1-6烷基,三氟甲基或C1-6烷氧基; X2代表氢或卤素; Y代表化学键,氧原子或—NH—链; Z代表可选取代的芳基或杂芳基; R1代表氢,碳氢化合物,杂环基,卤素,氰基,三氟甲基,硝基,—ORa,—SRa,—SORa,—SO2Ra,—SO2NRaRb,NRaRb,—NRaCORb,—NRaCO2Rb,—CORa,—CO2Ra,—CONRaRb或—CRa&═NORb; Ra和Rb独立地代表氢,碳氢化合物或杂环基; 还公开了包含该化合物的制药组合物;其在治疗方法中的应用;用于制造药物的应用;以及使用该化合物预防或治疗焦虑、惊厥或认知障碍的方法。